No Data
First Pharmaceutical: Report of Shanghai First Pharmaceutical Co., Ltd. Third Quarter 2024
Shanghai First Pharmaceutical Co., Ltd. Report for the Third Quarter of 2024
Shanghai First Pharmaceutical Co., Ltd. operating data announcement for the third quarter of 2024
Shanghai no.1 pharmacy (600833.SH) released its performance for the first three quarters, with a net income of 0.147 billion yuan, a year-on-year increase of 156.21%.
shanghai no.1 pharmacy (600833.SH) disclosed the third quarter report of 2024, achieving revenue of 13...
Shanghai No. 1 Pharmacy (600833.SH): The net income in the first three quarters was 0.147 billion yuan, a year-on-year increase of 156.21%.
On October 30th, Shanghai No. 1 Pharmacy (600833.SH) released its third quarter report, reporting a revenue of 1.369 billion yuan for the first three quarters, a year-on-year growth of 2.48%, net income of 0.147 billion yuan, a year-on-year increase of 156.21%, non-GAAP net income of 7.81 million yuan, a year-on-year decrease of 70.21%, and an EPS of 0.6604 yuan.
Shanghai No.1 Pharmacy (600833.SH): In the future, the company will continue to strengthen and optimize its business through strategies such as supplementing and encrypting network expansion around the '15-minute life circle'.
Shanghai No.1 Pharmacy (600833.SH) stated at the performance briefing on October 15th that in the future, the company will continue to optimize and strengthen its business by enhancing the business expansion strategy centered around the "15-minute life circle," improving professional service capabilities, strengthening the supply chain foundation, enhancing logistics efficiency, increasing marketing promotion, and rapidly expanding online channels.
Why Investors Shouldn't Be Surprised By Shanghai No.1 Pharmacy Co.,Ltd.'s (SHSE:600833) Low P/ENo Data
No Data
